Impact BioMedical Inc
Research Impact BioMedical Inc (IBO) on Bullrun: market cap USD 49.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIBO
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 49.60M
- Financial periodQ2 2026
- RevenueUSD 3.00K
- Net income-USD 699.00K
- Free cash flowUSD 470.00K
- Gross margin66.7%
Valuation Snapshot
latest market cap is USD 49.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 32.00K | -USD 11.84M | -USD 1.89M | -1225.0% | -0.38 | USD 3.00K | USD 22.88M | USD 12.31M |
| FY2024 | USD 0 | -USD 24.71M | -USD 3.12M | n/a | -2.3 | USD 2.00M | USD 8.88M | USD 4.26M |
| FY2023 | n/a | -USD 4.34M | n/a | n/a | -0.07 | USD 1.00K | USD 12.07M | USD 25.22M |
| FY2022 | USD 50.00K | -USD 7.26M | n/a | n/a | -0.1 | USD 2.00K | n/a | USD 29.56M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 49.60M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 52.31M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 16.68M | n/a | n/a | n/a |
About Impact BioMedical Inc
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Impact BioMedical Inc's market cap?
Impact BioMedical Inc's market capitalization is USD 49.60M.
What does Impact BioMedical Inc do?
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.